Deepcure was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists, and biologists. Using an end-to-end drug discovery platform and automated robotic wet lab, the Company is developing a novel pipeline of precision small molecules across many different therapeutic indications. DeepCure’s founding team includes some of the industry’s preeminent researchers and technologists. Our vision is to use AI-driven discovery to create better small molecules therapeutics and faster cures for every disease-relevant protein target.

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and more affordable way. At DeepCure, we reimagine the discovery pipeline using our AI platform to search the enormous chemical space with state-of-the-art accuracies. By combining the power of our Deep Learning algorithms, Cloud Computing infrastructure, and proprietary database of one Trillion chemistries, DeepCure's platform finds drug candidates that deliver improved value to patients. 

Our mission is to uncover new chemical horizons and enable discovery of "improbable" small-molecule therapeutics, delivering immense value to patients in need. DeepCure's AI algorithms analyze a trillion drug candidates from our proprietary virtual library and accurately point out the most promising ones while accounting for the dynamic nature of the target and optimizing the required ADMET properties.